0001209191-20-045144.txt : 20200805 0001209191-20-045144.hdr.sgml : 20200805 20200805165109 ACCESSION NUMBER: 0001209191-20-045144 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200803 FILED AS OF DATE: 20200805 DATE AS OF CHANGE: 20200805 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sandercock Colin CENTRAL INDEX KEY: 0001724870 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38327 FILM NUMBER: 201078305 MAIL ADDRESS: STREET 1: 21 ERIE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cue Biopharma, Inc. CENTRAL INDEX KEY: 0001645460 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473324577 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 21 ERIE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-949-2680 MAIL ADDRESS: STREET 1: 21 ERIE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Imagen Biopharma, Inc. DATE OF NAME CHANGE: 20150617 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-08-03 0 0001645460 Cue Biopharma, Inc. CUE 0001724870 Sandercock Colin 21 ERIE STREET CAMBRIDGE MA 02139 0 1 0 0 SVP, General Counsel and Sec Common Stock 2020-08-03 4 M 0 6425 7.50 A 23550 D Common Stock 2020-08-03 4 S 0 6425 20.00 D 17125 D Common Stock 2020-08-04 4 M 0 201 7.50 A 17326 D Common Stock 2020-08-04 4 S 0 201 20.05 D 17125 D Stock Option (right to buy) 7.50 2020-08-03 4 M 0 6425 0.00 D 2024-12-27 Common Stock 6425 143575 D Stock Option (right to buy) 7.50 2020-08-04 4 M 0 201 0.00 D 2024-12-27 Common Stock 201 143374 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. These Stock Options become exercisable in eight equal semi-annual installments beginning June 5, 2018. /s/ Colin Sandercock by Mark Busch, as attorney-in-fact 2020-08-05